NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis $3.20 -0.25 (-7.10%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cyclerion Therapeutics Stock (NASDAQ:CYCN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range$3.19▼$3.4550-Day Range$2.40▼$3.7052-Week Range$1.27▼$9.47Volume2,362 shsAverage Volume1.45 million shsMarket Capitalization$8.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More… Cyclerion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCYCN MarketRank™: Cyclerion Therapeutics scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cyclerion Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclerion Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclerion Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cyclerion Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.79% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.79% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 9.07%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentCyclerion Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cyclerion Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for CYCN on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCN Stock News HeadlinesCyclerion Therapeutics files $25M mixed securities shelfFebruary 5, 2025 | markets.businessinsider.com3 US Penny Stocks With Market Caps Over $10M To ConsiderFebruary 5, 2025 | finance.yahoo.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 1, 2025 | Golden Portfolio (Ad)Looking Into Cyclerion Therapeutics's Recent Short InterestJanuary 3, 2025 | benzinga.comCyclerion Therapeutics announces update on next stage of growthDecember 18, 2024 | markets.businessinsider.comCyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company GrowthDecember 17, 2024 | finance.yahoo.comCyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company GrowthDecember 17, 2024 | globenewswire.comCyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comSee More Headlines CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed this year? Cyclerion Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, CYCN shares have decreased by 0.5% and is now trading at $3.2050. View the best growth stocks for 2025 here. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, March, 4th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $1.81 million for the quarter. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics's stock reverse split on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings3/04/2025Today5/01/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCN CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,260,000.00 Net MarginsN/A Pretax Margin-2,722.68% Return on Equity-55.32% Return on Assets-48.35% Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick Ratio5.07 Sales & Book Value Annual Sales$2 million Price / Sales4.67 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.75Miscellaneous Outstanding Shares2,710,000Free Float1,732,000Market Cap$9.35 million OptionableNo Data Beta1.96 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:CYCN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.